Recursion Pharmaceuticals, Inc. RXRX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$117.5M-8.7% | -$108.12M+33.4% | -$162.25M+5.6% | -$171.9M+15.1% | -$202.49M-13.2% | ||
| $19.67M+1.0% | $19.48M-7.4% | $21.04M-11.8% | $23.85M+23.4% | $19.33M+49.3% | ||
| $22.22M-6.5% | $23.76M-5.9% | $25.24M-3.5% | $26.16M-27.5% | $36.06M+17.1% | ||
| -$81.1M-76.0% | -$46.07M+60.7% | -$117.36M-53.6% | -$76.42M+42.1% | -$131.96M-14.3% | ||
| $258K-79.3% | $1.24M+412% | $243K-92.3% | $3.15M+71.9% | $1.83M+41.1% | ||
| -$338K+72.8% | -$1.24M+51.2% | -$2.55M+56.1% | -$5.81M+20.1% | -$7.27M-103% | ||
| $2.21M+1.9% | $2.17M+1.9% | $2.13M+2.1% | $2.08M+1.8% | $2.05M-2.6% | ||
| -$3.47M-103% | $132.01M-47.5% | $251.34M+157% | $97.66M+141% | $40.53M+281% | ||
| -$88.74M-202% | $86.78M-34.9% | $133.3M+440% | $24.69M+126% | -$93.87M-156% | ||
| -$81.36M-71.9% | -$47.32M+59.8% | -$117.6M-47.8% | -$79.57M+40.5% | -$133.79M-14.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Recursion Pharmaceuticals, Inc.'s cash flow data come from?
- Every line is extracted from Recursion Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.